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Abstract
Background: MicroRNAs (miRNAs) are small, noncoding RNA molecules of 20 to 22 nucleotides that regulate gene
expression by binding to their 39 untranslated region (39UTR). Increasing data implicate altered miRNA participation in the
progress of cancer. We previously reported that CYP2J2 epoxygenase promotes human cancer phenotypes. But whether
and how CYP2J2 is regulated by miRNA is not understood.
Methods and Results: Using bioinformatics analysis, we found potential target sites for miRNA let-7b in 39UTR of human
CYP2J2. Luciferase and western blot assays revealed that CYP2J2 was regulated by let-7b. In addition, let-7b decreased the
enzymatic activity of endogenous CYP2J2. Furthermore, let-7b may diminish cell proliferation and promote cell apoptosis of
tumor cells via posttranscriptional repression of CYP2J2. Tumor xenografts were induced in nude mice by subcutaneous
injection of MDA-MB-435 cells. The let-7b expression vector, pSilencer-let-7b, was injected through tail vein every 3 weeks.
Let-7b significantly inhibited the tumor phenotype by targeting CYP2J2. Moreover, quantitative real-time polymerase chain
reaction and western blotting were used to determine the expression levels of let-7b and CYP2J2 protein from 18 matched
lung squamous cell cancer and adjacent normal lung tissues; the expression level of CYP2J2 was inversely proportional to
that of let-7b.
Conclusions: Our results demonstrated that the decreased expression of let-7b could lead to the high expression of CYP2J2
protein in cancerous tissues. These findings suggest that miRNA let-7b reduces CYP2J2 expression, which may contribute to
inhibiting tumor phenotypes.
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Introduction
Human cytochrome P450 (CYP) epoxygenase, CYP2J2, cata-
lyzes the epoxidation of arachidonic acid into four regioisomers of
cis-epoxyeicosatrienoic acid (5,6-EET; 8,9-EET; 11,12-EET; and
14,15-EET) [1]. This enzyme seems to be primarily expressed in
heart and vessel endothelial cells [2], and it has also been found in
a variety of tissues including liver, lung, kidney, and gastrointes-
tinal tissues [3]. Because differences in the catalytic efficiency of
individual P450 isoforms results in different EET profiles for each
[4], 11,12- and 14,15-EETs are the primarily arachidonic acid
metabolites produced in various cells and tissues [5,6].
Several studies have reported that EETs have diverse biological
effects within the cardiovascular system. The EETs released from
the endothelium activated calcium-sensitive potassium channels
and resulted in hyperpolarization of smooth muscle cells and
vascular relaxation [7]. Moreover, physiological concentrations of
EETs or overexpression of CYP2J2 reduced vascular cell adhesion
molecule-1 (VCAM-1) expression and prevented leukocyte adhe-
sion to the vascular wall [8]. The inhibitory effects of EETs show
that they have anti-inflammatory effects in vascular system
independent of their membrane-hyperpolarizing effects [8]. In
addition, EETs also promoted endothelial cell proliferation,
migration, and angiogenesis by activating both mitogen-activated
protein kinase (MAPK) and phosphatidylinositol-3 (PI3)-kinase/
Akt pathways [9].
On the other hand, other evidences indicate that epoxygenase
overexpression or EETs treatment have potentially deleterious
effects. In recent publications, CYP2J2-derived EETs were found
to play important roles in a host of processes related to cancer
cell behavior and tumor pathogenesis. We found high expression
of CYP2J2 in human tumors, as well as in eight human-derived
carcinoma cell lines, but not in adjacent normal tissues and
nontumoral human cell lines [10]. Overexpression of CYP2J2 or
addition of exogenous EETs markedly accelerated proliferation
and metastasis of cancer cells in vitro and in vivo [10,11].
CYP2J2 overexpression or addition of exogenous EETs protected
human carcinoma cells from apoptosis by upregulating the
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the proapoptotic protein, Bax [10]. In contrast, selective
inhibitors of CYP2J2 had significant antitumor effects in vitro
and in vivo and were associated with reduced EET biosynthesis
[12]. Collectively, all the findings demonstrated the important
and previously unrecognized roles of CYP2J2 and its EET
products in carcinogenesis.
Increasing evidences indicate that miRNAs play important roles
in diverse biological processes, such as proliferation, differentia-
tion, and apoptosis during development [13,14,15]. Several studies
have indeed described the aberrant expression in human tumors of
miRNAs and their function controlling the expression of certain
oncogenes and tumor suppressor genes [16,17,18]. For example,
miR-15a and miR-16 are frequently deleted or downregulated in
squamous cell carcinomas and adenocarcinomas of the lung [19].
MicroRNA-101 is downregulated in bladder transitional cell
carcinoma (TCC) tissues and inhibits cell proliferation and colony
formation in TCC cell lines by directly repressing oncogene EZH2
[20]. A recent study indicated that miRNA-let-7a inhibits the
expression of MYC and reverses MYC-induced growth in Burkitt
lymphoma cells [21]. Previous reports indicate that let-7 is poorly
expressed in a variety of human tumors and reduced let-7 level
results in over-expression (cyclinD, RAS, MYC) of let-7-responsive
genes in tumors [22,23,24,25]. However, the exact role of let-7 in
cancer is not yet fully understood. Our preliminary data show that
let-7b is down-regulated in human lung squamous tumors, while
levels of CYP2J2 protein is up-regulated, suggesting that human
CYP2J2 might be post-transcriptionally regulated by let-7b.
Hence, the purpose of the present study was to investigate this
hypothesis that let-7b might act as a tumor suppressor through
targeting CYP2J2.
Results
Let-7b Targets the 39UTR of CYP2J2
To investigate if CYP2J2 is regulated directly by let-7b, we
constructed a luciferase reporter plasmid containing the 39UTR
of CYP2J2 cloned downstream of the luciferase reporter gene
(Figure 1A). We transfected the luciferase construct into HepG2
cells together with let-7b or random let-7b. We found that
transfection of pMIR/CYP2J2-39UTR along with let-7b result-
ed in a significant reduction in reporter activity than did those
of control and random transfections. On the other hand, no
significant downregulation of the pMIR reporter activity could
be determined when we transfected the pMIR reporter (empty
vector) along with let-7b or random let-7b into HepG2 cells
(Figure 1B). To further confirm that CYP2J2 is a target of let-
7b, we constructed seven mutants (pMIR/CYP2J2-3?UTR
mutant, mutant-1, mutant-2 … and mutant-6, respectively)
based on pMIR/CYP2J2-3?UTR. Then we transfected these
constructs into the cells (MDA-MB-435 and SK-MES-1) and
analyzed luciferase reporter activity. The assays showed that
luciferase activity of pMIR/CYP2J2-3?UTR mutant was not
repressed by let-7b, compared with the wild type pMIR/
CYP2J2-3?UTR (Figure 1C and D). Among the remaining six
mutants (mutant-1, mutant-2…mutant-6), luciferase activity of
mutant-3 was repressed by let-7b, comparing with random and
control (P,0.05) (Figure 1E). Furthermore, binding site III
completely matched the seed sequence of let-7b if wobble base
pairing was allowed. These data indicate that CYP2J2 is one of
the targets of let-7b.
Let-7b Inhibits Expression Levels of Endogenous CYP2J2
and its Enzymatic Activity in vitro
To investigate the effects of exogenous let-7b on the protein
level and enzymatic activity of endogenous CYP2J2 proteins, we
examined the protein levels of CYP2J2 in HeLa, Tca-8113, SK-
MES-1, and MDA-MB-435 cells after treatment with let-7b for
48 h (100 nM). Western blot analysis showed that overexpres-
sion of let-7b significantly downregulated the expression of
CYP2J2 in four cancer cell lines (Figure 2A). Relative CYP2J2
expression was quantified by densitometry (Figure 2B). As in
Figure S1A and B, western blots showed dose-dependent effect
of let-7b and let-7b inhibitor on CYP2J2 protein expression.
Given the instability of EETs, we determined concentration of
the stable metabolite 14,15-DHET in cell culture media to
confirm inhibition of let-7b on the enzymatic activity of
CYP2J2. The results showed that 14,15-DHET levels were
significantly decreased by the transfection of let-7b (Figure 2C).
These data showed that human CYP2J2 is directly downreg-
ulated by let-7b.
Let-7b Reduces Cancer Cell Growth and Induces
Apoptosis by Directly Downregulating CYP2J2
We have previously reported that CYP2J2 stimulates prolif-
eration of carcinoma cells and protects human carcinoma cells
from apoptosis [10]; so it was of interest to evaluate the effects
of overexpression of let-7b on cell proliferation and apoptosis
when endogenous CYP2J2 was inhibited by let-7b. We treated
HeLa, Tca-8113, SK-MES-1, and MDA-MB-435 cells with
exogenous let-7b or random let-7b for 48 h. The proliferation
rate was determined via Cell-Light
TM EDU DNA Cell
Proliferation Kit (Ribobio, China). The results showed a
significant inhibition of cell proliferation by let-7b. For example,
in MDA-MB-435 and SK-MES-1 cells, let-7b reduced cell
proliferation by 50% compared with negative control and
random let-7b (Figure 3A). Apoptosis, measured by Annexin V
and propidium iodide staining, significantly increased in cells
transfected with let-7b (Figure 3B). In addition, exogenous let-7b
decreased the percentage of EDU-positive cells and increased
the apoptotic cells in HeLa and Tca-8113 cells (Figure 3C and
D). To provide further evidence that the effects of let-7b
expression on cell proliferation and apoptosis were related to
CYP2J2, cells transfected with let-7b were treated with C26
(10 mM) (specific CYP2J2 inhibitor [12] ) and 14,15-EET
(250 nM) for 48 h. To minimize reduction in levels of 14,15-
EET due to autooxidation, cells were stimulated with 14,15-
EET or a comparable volume of vehicle (DMSO) every 6 h. As
expected, the effects of let-7b expression on cell proliferation
and apoptosis were enhanced by C26 and abolished by 14,15-
EET (Figure 3E and F). In addition, to determine whether let-
7b treatment affect cell growth of H9c2 (H9c2 cells do not have
CYP2J2), we used Cell-Light
TM EDU DNA Cell Proliferation
Kit and Annexin V and propidium iodide staining to measure
the cell proliferation and apoptosis of H9c2 cells. As shown in
Figure S2A and B, not only cell proliferation but also cell
apoptosis of H9c2 cells weren’t affected by let-7b or let-7b
inhibitor treatment. These data suggested that overexpression of
let-7b resulted in decreased proliferation and activated apoptosis
of carcinoma cell lines.
We also investigated the influences of let-7b on the expression of
proapoptotic protein Bax and antimetastatic protein nm-23 and
the activation of the PI3K/Akt and MAPK signaling pathways,
which play important roles in P450 epoxygenase- and EET-
mediated tumorigenesis and metastasis [10,11,12]. We found that
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regulated the PI3K, pAkt, pERK pathways but increased Bax and
nm-23 expression (Figure 3G). Similar results were also observed
in MDA-MB-435 cell which treated with let-7b agomir (Figure
S1C and D). However, let-7b did not affect PI3K, pAkt, and Bax
of H9c2 cells (Figure S2C). We speculated that this is because
H9c2 cells do not have CYP2J2. These results indicated that the
enhancing effect of CYP2J2 on tumor formation could be
attenuated by let-7b.
Expression Level of CYP2J2 Protein and let-7b in Human
Lung Cancer and in Adjacent Normal Tissues are
Inversely Correlated
To investigate an association between let-7b level and the
expression of CYP2J2 in human carcinomas, the expression of
CYP2J2 protein and let-7b in 18 paired human lung squamous
cancer tissues and adjacent nontumor tissues was examined by
western blot analysis and real-time RT-PCR, respectively. Results
showed that CYP2J2 was highly expressed in the majority of
Figure 1. Identification of CYP2J2 as a direct target of let-7b. A, schematic representation of the predicted target sites of let-7b in the 39UTR
of CYP2J2. The 39UTR of CYP2J2 was cloned into a luciferase reporter plasmid, termed pMIR/CYP2J2-39UTR. A series of mutants carried mutated
nucleotides in six potential binding sites for the let-7b seed region were generated based on wild type pMIR/CYP2J2-39UTR. Mutants of pMIR/CYP2J2-
39UTR are constructed by mutating the complementary site (labeled by underline) in the let-7b seed region to their complementary bases. B,
luciferase activity was analyzed in HepG2 cells 24 h after transfection with reporter plasmid pMIR/CYP2J2-39UTR or pMIR (empty vector). C–D, full-
length sequence CYP2J2-39UTR containing mutant binding sites for the let-7b seed region were generated based on wild type pMIR/CYP2J2-39UTR.
We transfected these constructs into the cells (MDA-MB-435 and SK-MES-1) and analysed luciferase reporter activity. As we expected, let-7b did not
affect luciferase activity of mutants compared with wild type. E, the six mutants were transfected into SK-MES-1 cells, in addition to let-7b or random
let-7b. The luciferase activity of the six mutants was not repressed by let-7b. Renilla luciferase activities were used to normalize firefly luciferase
activity. Columns, mean of three experiments; bars, SD. *, P,0.05.
doi:10.1371/journal.pone.0039197.g001
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(Figure 4A). Real-time RT-PCR was used to determine the mature
let-7b levels in 18 paired human lung squamous cancer tissues and
adjacent nontumor tissues. Although changes of 2DDCT values
[2(DCTnon-tumor tissue2DCTcancer tissue)] were relatively mild (from
21.85 to 5.4, 2.661.27), the fold change (2
2DDCT) of let-7b
expression between 18 paired human lung squamous cancer
tissues and adjacent nontumor tissues was significant (from 0.277
to 42.22, 6.0662.43). Consequently, the results showed that levels
of mature let-7b were significantly decreased in 14 lung tumors
compared with their matched controls among 18 samples analyzed
(Figure 4B). We next investigated a correlation between let-7b
expression level and CYP2J2 protein level in human lung
squamous cancer tissues. And there is statistically significant
inverse correlation between let-7b expression level and CYP2J2
protein level in 18 sets of lung squamous tumors cancer and paired
adjacent nontumor tissues (Figure 4C). Furthermore, we found
that CYP2J2 had inverse expression levels to let-7b in four paired
human breast cancer and adjacent nontumor tissues (Figure 4D
and E). And let-7b expression in SK-MES-1 and MDA-MB-435
cells was shown in Figure S3.
Let-7b-mediated Knockdown of CYP2J2 Inhibits Tumor
Growth and Metastasis
Furthermore, we investigated the influence of let-7b on tumor
growth in an in vivo model. To generate a tumor xenograft
model, 2610
6 MDA-MB-435 cells were injected subcutaneously
into the right flank of nude mice. Two weeks after injection,
when tumors had grown to approximately 40 mm
3, the let-7b
expression vector pSilencer-let-7b was injected into mice at a
dose of 4 mg/kg body weight through tail vein every 3 weeks. As
expected, mice injected with pSilencer-let-7b via tail vein showed
a significant reduction in tumor volume compared to the controls
(Figure 5A). During the treatment period, we determined the
14,15-DHET level in the urine of nude mice and found a
significant reduction in 14,15-DHET in the let-7b treatment
group compared with the controls (Figure 5B). At the end of the
treatment period, let-7b resulted in significantly decreased tumor
weight, but body weight had not changed (Figure 5C). We also
treated MDA-MB-435 cell with let-7b agomir (150 nM) or
agomir control for 48 h, and then injected these cells into the
right flank of nude mice. After 4 weeks, necropsies were
performed, and all tumors per mouse were weighed. Let-7b
agomir resulted in significantly decreased tumor weight (Figure
S4). Furthermore, the level of mature let-7b was validated by
real-time RT-PCR; results showed that pSilencer-let-7b treat-
ment resulted in a significant increase in both tumor and organs
(Figure 5D and E). Western blot analysis showed a markedly
decreased expression level of CYP2J2 protein and a significantly
increased expression level of proapoptotic protein Bax and
antimetastatic protein nm-23 in the let-7b-treated mice com-
pared with controls (Figure 5F). These results suggest that let-7b
Figure 2. Effect of exogenous let-7b on CYP2J2 expression and its enzymatic activity. A, protein level of CYP2J2. HeLa, Tca-8113, MDA-
MB-435, and SK-MES-1 cells were treated with let-7b or random let-7b (100 nM) for 48 h. The protein level of CYP2J2 was examined by western blot
analysis. B, protein level of CYP2J2 was quantified by densitometry. Columns, mean of three experiments; bars, SD. *, P,0.05. C, stable metabolite 14,
15-DHET in HeLa, Tca-8113, and MDA-MB-435 cells were determined as described under Materials and Methods. Cells treated with exogenous hsa-let-
7b produced fewer EETs than those treated with random let-7b. Points, mean of three experiments; bars, SD. *, P,0.05.
doi:10.1371/journal.pone.0039197.g002
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CYP2J2.
Furthermore, we evaluated whether overexpression of let-7b
affected metastasis. At the end of the experiment, spleens were
removed and incised vertically to count metastatic tumor colonies.
Metastases in longitudinal section of the spleen were visible to the
naked eye as nodules. We observed a significant decrease in the
average number of spleen metastases in mice injected with
pSilencer-let-7b compared with controls (Figure 6A). We also
determined the extent of lymph node metastasis by measuring the
weight of lymph nodes. We found that injection of pSilencer-let-7b
through tail vein reduced the average weight of axillary lymph
nodes (Figure 6B). Further histological analysis after hematoxylin
and eosin staining of paraffin sections showed a marked difference
between athymic mice treated with let-7b and controls (Figure 6C
and D): the let-7b treatment caused a significant increase in the
incidence of necrotic regions in tumor and spleen. Compared with
the control group, the metastases focis were smaller and fewer in
sections of spleen of the let-7b treatment group. Furthermore,
TUNEL staining of sections showed that let-7b treatment resulted
in a significant increase in TUNEL-positive cells in tumors and in
mice spleen (Figure 6E and F). These data indicate that let-7b
treatment can inhibit tumor metastasis.
Discussion
In the present study, we have shown a new mechanism for
controlling the tumor-promotion function of CYP2J2. Bioinfor-
matics analysis predicted that let-7b is a potential regulator of
CYP2J2 gene. Using CYP2J2-expression cancer cell lines and a
tumor xenografs model, we have shown that human CYP2J2 is
posttranscriptionally regulated by let-7b and that the posttran-
scriptional regulation is responsible for the tumor-promotion
function of CYP2J2. Furthermore, in human lung squamous
cancer and adjacent nontumor tissues, we observed a reverse
relationship between let-7b and CYP2J2 expression levels.
It has become apparent that microRNAs regulate the expression
of target genes by binding to the complementary regions of the
39UTR of their target genes [26], but whether hsa-let-7b regulates
human CYP2J2 expression is not known. Previous study has
shown that let-7 regulates RAS through its 39UTR [27]. In the
present study, luciferase assays showed that let-7b repressed the
activity of the reporter construct containing the 39UTR region of
CYP2J2 mRNA. Transfection of carcinoma cell lines with let-7b
and injection of pSilencer-let-7b producing mature let-7b in vivo
decreased CYP2J2 protein expression and enzymatic activity,
suggesting that CYP2J2 is posttranscriptionally negatively regulat-
ed by let-7b.
Recent studies have demonstrated that let-7 might act as a
tumor suppressor and that reduced let-7 level results in let-7-
responsive gene (cyclinD, RAS, MYC, etc.) overexpression in
tumors [22,23,24,25]. With western blot analysis and real-time
RT-PCR, we showed higher expression of CYP2J2 protein and
lower expression of let-7b in 18 paired human lung squamous
cancer tissues compared with the adjacent nontumor tissues. Thus,
the high expression of CYP2J2 protein in cancer tissues may result
from the decreased expression of let-7b, at least in part. Of course,
it is likely that another mechanism(s) is involved in regulating
CYP2J2 expression. Our previous study showed that overexpres-
sion of CYP2J2 or additing exogenous EETs decreased apoptosis
and increased cell proliferation in cancer cell lines and increased
tumor growth and lung metastasis in a murine xenograft model
[10]. Furthermore, we recently found that Compound 26, the
selective inhibitor of CYP2J2, significantly repressed the tumor-
promotion function of CYP2J2 [12].
In the present study, we described a new mechanism for
suppression of CYP2J2. We treated carcinoma cell lines with let-
7b and found that overexpression of let-7b resulted in decreased
proliferation and activated apoptosis of cancer cells. We also found
thatpSilencer-let-7btreatmentsignificantlyinhibitedtumorgrowth
in a tumor xenograft model. Although downregulation of CYP2J2
by pSilencer-let-7b did not result in the eradication of tumors, the
reverse correlation between the expression level of CYP2J2 and let-
7b in human cancer tissue and the effectiveness of inhibiting the
tumor-promoting functions of CYP2J2 revealed the potential
therapeutic benefit of let-7b in human cancers.
In our previous study, we reported that EETs protect
endothelial cells from apoptosis by activating the phosphatidyli-
nositol 3-kinase (PI3K)/Akt and MAPK signaling pathways [25].
In the current study, overexpression of let-7b suppressed the
expression of CYP2J2 protein and its EET products in vitro and in
vivo. We also found that let-7b could inhibit the proliferation, and
enhance the apoptosis, of human tumor cells by inhibiting the
PI3K/Akt and MAPK signaling pathways and by activating the
proapoptotic protein Bax and antimetastatic protein nm-23, both
of which are involved in P450 epoxygenase- and EET-mediated
tumorigenesis and metastasis [10]. Our data suggest that the effect
of CYP2J2-derived EETs on tumor formation was mediated by
let-7b. The 11 members of the let-7 family have similar target
genes and functions on cell proliferation because of the high
similarity among their sequences [23,28]. In the present study, we
focused on the effect of let-7b on the expression of CYP2J2. Effects
of the other members of let-7 family on CYP2J2 expression and
cancer cell proliferation need further study.
In conclusion, our data confirmed that let-7b expression is
frequently decreased in lung squamous cell cancers. Our work also
indicated that human CYP2J2 is posttranscriptionally regulated by
let-7b, which results in the high expression of CYP2J2 protein in
human carcinomas. Our study demonstrated a new mechanism
whereby CYP2J2- and EET-mediated tumorigenesis and metas-
tasis are associated with let-7b. Besides MYC and RAS, let-7b can
function as a tumor suppressor by blocking CYP2J2.
Figure 3. Influence of let-7b on cell proliferation and apoptosis. A, proliferation assay via Cell-Light
TM EdU DNA Cell Proliferation Kit showing
decreased proliferation rate of MDA-MB-435 and SK-MES-1 cells treated with let-7b compared to the cells treated with random let-7b or control. The
blue-stained cells were stained by Hoechst, and the red were EdU add-in cells. EdU-positive cells were calculated as (EdU add-in cells/Hoechst-stained
cells)6100%. Columns, mean of three experiments; bars, SD. *, P,0.05. B, percentage of apoptotic cells was increased in MDA-MB-435 and SK-MES-1
cells treated with let-7b. Apoptosis measured by annexin V-FITC (x-axis) and propidium iodide staining (y-axis). Percentages of apoptotic cells
(percentage of cells in the upper-right quadrant (annexin V-positive, PI-negative) plus cells in the low-right quadrant (annexin V-positive, PI-positive)
in total cell number) are given under the relevant graph. Columns, mean of three experiments; bars, SD. *, P,0.05. C–D, percentages of EdU-positive
cells and apoptotic cells were analyzed in HeLa and Tca-8113 cells transfected with let-7b or random let-7b. E–F, MDA-MB-435 and SK-MES-1 cells
transfected with let-7b were treated with C26 (specific CYP2J2 inhibitor, 10 mM) or 14,15-EET (250 nM). 48 h later, percentages of EdU-positive cells
and apoptotic cells were analyzed. Columns, mean of three experiments; bars, SD. *, P,0.05. G, let-7b overexpression influenced expression of
tumor-related genes in MDA-MB-35 cells. Let-7b overexpression in MDA-MB-435 cells significantly downregulated PI3K, pAkt, and pERK but increased
Bax and nm-23 expression. The data shown were repeated three times.
doi:10.1371/journal.pone.0039197.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39197Figure 4. Relationship between CYP2J2 protein and let-7b expression in lung cancer and adjacent nontumor tissues. A, expression
levels of CYP2J2 in lung cancerous (C) and adjacent nontumor tissues (N) was measured by Western blot analysis. B, comparison between the
expression levels of let-7b in lung cancerous and adjacent nontumor tissues (n=18). Although changes of 2DDCT values [2(DCTnon-tumor
tissue2DCTcancer tissue)] are relatively mild (from -1.85 to 5.4, 2.661.27), the fold changes of let-7b expression between 18 paired human lung
squamous cancer and adjacent nontumor tissues are significant (from 0.277 to 42.22, 6.0662.43). C, relationship between CYP2J2 protein and let-7b
expression in lung cancer and paired adjacent nontumor tissues. Expression level of CYP2J2 protein was increased in 13 of 18 sets of lung cancer
compared with the adjacent normal tissues (the fold change.1). As expected, let-7b levels were commonly reduced in these tumors compared with
the adjacent normal tissues (the fold change,1). D–E, expression levels of CYP2J2 and let-7b in breast cancerous and adjacent nontumor tissues
(n=4). Real-time RT-PCR was used to determine mature let-7b levels. The U6 snRNA expression level was used to normalize the relative let-7b level.
Columns, mean of three experiments; bars, SD. *, P,0.05.
doi:10.1371/journal.pone.0039197.g004
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Ethics Statement
This study was approved by the Review Board of Tongji
Hospital and Tongji Medical College. The recruited subjects
provided written informed consent. The investigation conforms to
the principles outlined in the Declaration of Helsinki. All animal
experimental protocols complied with the ‘‘Guide for the Care and
Use of Laboratory Animals’’ published by the United States
National Institutes of Health.
Cell Lines
The human cervix adenocarcinoma cell line HeLa, human
hepatoma liver cell line HepG2, human tongue squamous cell
carcinoma Tca-8113, and human lung squamous cancer cell line
SK-MES-1 were obtained from the American Type Culture
Collection (Manassas, Virginia). Cells were maintained in
Figure 5. Effect of let-7b on tumor growth. MDA-MB-435 cells were injected subcutaneously into the right flank of nude mice to generate the
mouse model of breast cancer. Two weeks later, mice received the let-7b treatment randomly. The let-7b expression vector (pSilencer-let-7b plasmid)
was injected into mice through a tail vein at a dose of 4 mg/kg body weight every 3 weeks. A, the x-axis was labeled as the days of pSilencer-let-7b
treatment. Tumor volume was measured weekly and calculated as TV (mm
3) = length6width
260.5236. B, the measurement of 14,15-DHET level in
nude mice urine was performed by ELISA according to the manufacturer’s instructions. Points, mean of three experiments; bars, SD. *, P,0.05. C,
average tumor weight and body weight of control and let-7b treatment groups after growth for 8 weeks. Columns, mean; bars, SD. *, P,0.05 versus
control. D–E, the expression of the mature let-7b in the tumors and primary organs was validated by real-time RT-PCR. Columns, mean of three
experiments; bars, SD. *, P,0.05. F, Western blot analysis showed alteration of the expression level of CYP2J2 protein and tumor-related genes of
tumor samples.
doi:10.1371/journal.pone.0039197.g005
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Carlsbad, California) with 10% fetal bovine serum (FBS) at
37uC in the presence of 5% CO2 at constant humidity. The MDA-
MB-435 human breast carcinoma cell line was also obtained from
the American Type Culture Collection and was grown in RPMI
1640 medium supplemented with 10% FBS and maintained at
37uC in 95% air/5% CO2.
MicroRNA Target Prediction
RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/cgi-bin/
rnahybrid_submit) was used for miRNA target prediction. We
found four potential target sites (site I, site III, site IV, and site VI)
in 39UTR of human CYP2J2 for let-7b. In addition, we also
compared the let-7b sequence to the full length sequence of
CYP2J2-39UTR with DNAMAN software (LynnonBiosoft, Que-
bec, Canada). We also found another two potential bingding sites
(site II and site V), besides the four potential target sites previously
described (Figure 1A).
Plasmid Construction
The full length sequence of human CYP2J2-3?UTR was
amplified by PCR using the primers 59-GCGACTAGTGTAT-
CACCATTTCCCCAGTCAGTCA-39 (CYP2J2-39UTR-former
primer) and 59-GCGAAGCTTCATGGGAATAAGTGTCT-
GATGGAGG-39 (CYP2J2-39UTR-reverse primer). To construct
luciferase reporter plasmids, the 39UTR sequence of CYP2J2 was
insertedintotheHindIIIandSacIsites,downstreamoftheluciferase
reporter gene in the pMIR-REPORT
TM Luciferase Vector
(Ambion, Carlsbad, California). This plasmid was termed pMIR/
CYP2J2-39UTR. Correspondingly, constructs containing CYP2J2-
39UTR withpoint mutations inthe seed sequence were constructed
using the Fast Mutagenesis System kit (TransGen, Biotech, China)
according to the manufacturer’s protocol. PMIR/CYP2J2-39UTR
mutant, which carried mutated sequence in the complementary site
for the let-7b seed region in all the six potential binding sites, was
generated based on the wild type plasmid pMIR/CYP2J2-39UTR.
Furthermore,theothersixplasmids,inwhichoneofthesixpotential
binding sites was wild and the other five putative binding sites were
mutated, were termed mutant-1, mutant-2, mutant-3, mutant-4,
mutant-5,andmutant-6,respectively.Forexample,theconstruct,in
which theseed-matching sequence ofsite Iwas notmutated andthe
otherfiveweremutated,wasnamedmutant-1.Mutant-2carriedthe
mutated seed-matching sequence of five binding sites except site II.
The remaining mutants were named by analogy (Figure 1A).
To construct the let-7b expression vector (pSilencer-let-7b), two
complementary single oligonucleotide strands, 59-GATCCAAC-
CACACAACCTACTACCTCATTCAAGAGATGAGGTAG-
TAGGTTGTGTGGTTA-39UTR and 59-AGCTTAACCACA-
CAACCTACTACCTCATCTCTTGAATGAGGTAG-
TAGGTTGTGTGGTTG-39UTR, were synthesized (AuGCT,
China). After an initial denaturation at 94uC for 3 min, the two
complementary oligonucleotides were incubated at 37uC for 1 h to
Figure 6. Let-7b overexpression inhibits tumor metastasis. A, average number of spleen metastases for each group (n=6). Columns, mean;
bars, SD. *, P,0.05 versus control. B, average weight of axillary lymph nodes for each group. Columns, mean; bars, SD. *, P,0.05 versus control. C–D,
hematoxylin and eosin staining of sections of tumor (C1, C2) and spleen (D1, D2). E–F, TUNEL staining of tumor (E1, E2) and spleen (F1, F2) sections.
doi:10.1371/journal.pone.0039197.g006
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were ligated into BamHI/HindIII sites of plasmid pSilencer 4.1-
CMV vector (Ambion, Carlsbad, California). This pSilencer-let-7b
plasmid expresses a let-7b RNA hairpin that yields mature let-7b.
Luciferase Assay
HepG2, MDA-MB-435, and SK-MES-1 cells were transfected
in 24-well plates by Lipofectamine 2000 (lipo2000) (Invitrogen,
Carlsbad, California) in accordance with the manufacturer’s
instructions. Cells were transiently transfected with 200 ng of the
luciferase constructs pMIR/CYP2J2-39UTR or the empty vector
and 10 ng of pRL-TK plasmid (Promega, Madison, Wisconsin). In
some cases, let-7b (mature let-7b) or random let-7b (Ribobio,
China) was cotransfected with reporter plasmids in a final
concentration of 100 nM. Random let-7b was the scrambled
oligonucleotide and used as negative control. Luciferase activity
was analyzed 24 h after transfection by using the Dual-Luciferase
Reporter Assay System (Promega, Madison, Wisconsin). Renilla
luciferase activities were used to normalize the transfection
efficiency and the internally controlled firefly luciferase activity.
Western Blotting
Cells grown in six-well plates were transfected with let-7b or
random let-7b to a final concentration of 100 nM. 48 h after
transfection, cells were harvested and homogenized with lysis
solution (50 mM Tris-Cl, pH 8.0; 150 mM NaCl; 0.02% sodium
azide; 0.1% SDS; 1 mg/ml aprotinin; 1% Nonidet P-40; and 0.5%
sodium deoxycholate) containing protease inhibitors (100 mg/ml
phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml leu-
peptin). Supernatant was collected after centrifuging at 12,0006g
for 20 min at 4uC. The protein concentration was measured using
the BCA protein assay reagent kit (Boster, China). Lysates were
resolved by 10% SDS-polyacrylamide gel electrophoresis and
transferred to polyvinylidene difluoride (PVDF) membranes. After
blocking with 5% nonfat milk, blots were probed with a specific
antibody and incubated with a peroxidase-conjugated secondary
antibody. Bands were visualized by enhanced chemiluminescence
reagents (Pierce Chemical, Rockford, Illinois) and quantified by
densitometry.
Determining 14,15-dihydroxyeicosatrienoic Acid Levels
Measuring EET and 14,15-DHET in the cultured cells and
urine of nude mice was performed as previously described
[10,11,12].
Cell Proliferation and Apoptosis Assays
Cell proliferation was monitored using Cell-Light EDU DNA
Cell Proliferation Kit (Ribobio, China). Cells grown in 96-well
plates were transfected with miRNA as described. Proliferation
assays were done 48 h after transfection following the manufac-
turer’s protocol. The blue-stained cells were stained by Hoechst,
and the red were EdU add-in cells. EdU add-in cells and Hoechst-
stained cells were counted in six randomly selected microscopic
fields per well. EdU-positive cell was calculated as (EdU add-in
cells/Hoechst stained cells) 6100%.
To measure the effects on cell apoptosis rates, cells were
harvested 48 h posttransfection and resuspended in binding buffer.
FITC-conjugated annexin V and propidium iodide (Keygentec,
China) were added to the cells, and samples were incubated for
15 min at room temperature. Cells were then analyzed with a
FACStar-Plus flow cytometer (BD Biosciences, Franklin Lakes,
New Jersey) to determine the percentage of apoptotic cells. We
calculated the percentage of apoptotic cells by the percentage of
cells in the upper-right quadrant (annexin V-positive, PI-positive)
plus cells in the lower right quadrant (annexin V-positive, PI-
negative) in the total number of cells.
RNA Extraction and Real-time PCR
Total RNA was extracted from frozen tissue samples by using
Trizol Reagent Kit (Invitrogen, Carlsbad, California) according to
the manufacturer’s instructions. Two micrograms of total RNA
were reverse-transcribed using a reverse transcription kit (Takara,
Japan). Quantification of miRNA was done by quantitative real-
time PCR according to the manufacturer’s protocol (Ribobio,
China). Expression of U6 small nuclear RNA (snRNA) was used as
an internal standard.
The specific primers were purchased from Ribobio Company
(Ribobio, China). The PCR profiles for human let-7b and human
U6 snRNA were performed as follows: after an initial denaturation
at 95uC for 20 s, amplification was finished by denaturing at 95uC
for 10 s, annealing at 60uC for 20 s, and extending at 70uC for 1 s
through 40 cycles.
Measuring Let-7b and CYP2J2 Levels in Human Lung
Cancerous and Adjacent Noncancerous Tissues
Lung cancerous and adjacent noncancerous tissues were
collected during surgical procedures at Tongji Hospital from 18
patients with lung squamous cell cancer. Informed consents were
obtained. In addition, breast cancer and adjacent noncancerous
tissues were also collected from four patients. The samples were
immediately frozen in liquid nitrogen and stored at 280uC. Paired
nontumor and tumor tissues were further examined by quantita-
tive real-time reverse transcription-PCR (qRT-PCR) for the
expression levels of let-7b and by Western blot analysis for
CYP2J2 as described above. This study was approved by the
Clinical Research Committee of Tongji Medical College and was
carried out according to the guidelines of the NIH.
Xenograft Model of Tumor Growth
All animal studies were approved by the Animal Research
Committee of Tongji Medical College and were carried out in
accordance with the guidelines of the NIH (approval ID: S215).
Male athymic BALB/C nude mice 4 weeks old were housed in
specific pathogen-free conditions on a daily 12-h light/12-h dark
cycle. MDA-MB-435 cells were harvested on the day of use and
injected subcutaneously into the right flank of the nude mice.
Approximately 2 weeks after implantation, when tumors had
grown to approximately 40 mm
3, mice were randomly divided
into control and let-7b precursor expression vector treatment
groups (n=16). Mice received either let-7b precursor expression
plasmid (pSilencer-let-7b) at a dose of 4 mg/kg body weight or a
comparable dose of empty plasmid pSilencer (dissolved in 100 ml
deionized water) as control through tail vein injection every 3
weeks. The mice were monitored daily and weighed weekly.
Tumor volume was calculated weekly according to the formula
(TV (mm
3) = length6width
260.5236). At the end of the
experiment, tumor xenografts were harvested, weighed, and
snap-frozen. Tissues were fixed in 3.7% formalin, embedded in
paraffin, and serially cut into 4-mm thick sections for hematoxylin
and eosin staining and TUNEL assay.
Terminal Deoxynucleotidyl Transferase–mediated dUTP
Labeling
Apoptosis in tissues was detected by using the TACSH 2 TdT
DAB In Situ Apoptosis Detection Kit according to the manufac-
turer’s instruction (R&D Systems, Minneapolis, Minnesota).
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and then immersed in 3% H2O2 for 5 min to quench endogenous
peroxidase. After being immersed in 16TdT Labeling Buffer for
5 min, the sections were incubated in TdT Labeling Reaction Mix
for 60 min at 37uC in a humidity chamber and then incubated
with 16TdT Stop Buffer for 5 min to stop the labeling reaction.
After deionized water washes, sections were incubated with Strep-
HRP solution for 10 min at 37uC, washed twice with 16PBS, and
immersed in DAB solution for 2 to 7 min. Sections were then
counterstained with methyl green, and the TUNEL-positive cells
were counted in five fields per tissue section.
Statistical Analysis
Data are presented as mean 6 SD from at least three separate
experiments. The data were analyzed by Student’s t-test. A P value
,0.05 was considered as significant for all tests.
Supporting Information
Figure S1 Effect of exogenous let-7b on CYP2J2 expres-
sion. A, MDA-MB-435 cells were treated with let-7b or let-7b
random (50 nM, 100 nM, 150 nM and 200 nM) for 48 hours.
The protein level of CYP2J2 was examined by western blot
analysis. B, MDA-MB-435 cells were treated with let-7b inhibitor
or inhibitor control (50 nM, 100 nM, 150 nM and 200 nM) for 48
hours. Expression of CYP2J2 was up-regulated by let-7b inhibitor.
C, MDA-MB-435 cells were treated with let-7b agomir (150 nM),
let-7b antagomir (150 nM) or negative control for 48 h.
Expression of CYP2J2 was down-regulated by let-7b agomir and
up- regulated by let-7b antagomir. D, western blot analysis was
used to detect the expression level of PI3K/AKT and BAX/nm-
23 in MDA-MB-435 cells treated with let-7b agomir or antagomir.
(TIF)
Figure S2 Influence of let-7b on cell proliferation and
apoptosis in H9C2 cell. A, proliferation assay via Cell-
LightTM EDU DNA Cell Proliferation Kit showing proliferation
rate of MDA-MB-435 cell treated with let-7b (150 nM) or let-7b
inhibitor (150 nM). Let-7b random and inhibitor control were
used as control. Columns, mean of three experiments; bars, SD. B,
percentage of apoptotic cells was increased in MDA-MB-435
treated with let-7b (150 nM) or let-7b inhibitor (150 nM).
Percentages of apoptotic cells (percentage of cells in the upper-
right quadrant (annexin V-positive, PI-negative) plus cells in the
low-right quadrant (annexin V-positive, PI-positive) in total cell
number) are given under the relevant graph. Columns, mean of
three experiments; bars, SD. C, Influence of let-7b or let-7b
inhibitor overexpression on expression of PI3K, pAkt, and pERK
and Bax in H9c2 cells. No significant difference of PI3K, pAkt,
and pERK and Bax protein expression level were observed in
H9c2 cells transfected with let-7b or let-7b inhibitor.
(TIF)
Figure S3 Expression of let-7b in SK-MES-1 and MDA-
MB-435 cells. Real-time RT-PCR was used to determine
mature let-7b levels. U6 served as an internal normalized
reference. Columns, mean of three experiments; bars, SD.
(TIF)
Figure S4 Tumor weight of MDA-MB-435 cells trans-
fected with agomir control or let-7b agomir. MDA-MB-
435 cell were transfected with let-7b agomir (150 nM) or agomir
control for 48 h, and then subcutaneously injected into the right
flank of nude mice. After 4 weeks, the mice were sacrificed,
necropsies were performed, and all tumors per mouse were
weighed. Columns, mean; bars, SD. *, P,0.05.
(TIF)
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